fashion -WSS

fashion

author：knowledge 2025-10-02 11:08:01 - browse：48519

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Humana’s losses in Medicare Advantage tank its stock

WSS

Humana’s losses in Medicare Advantage tank its stock

U.S. death rates show how politics are affecting public health

The world needs the new pandemic treaty

Guardant Health colon cancer test endorsed by FDA advisory panel

Stroke rates rising, especially in working

Investment in vaccine development is lagging, report finds

hotspot

fashion

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

The world needs the new pandemic treaty

Hepatitis C has a cure — but many Americans still lack access to it

Stroke rates rising, especially in working

Apple is now the first public company to be valued at $3 trillion

Vertex non

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Philips to halt sales of sleep apnea machines in U.S.

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage insurers face 0.2% cut to 2025 payments

hotspot

Should insurance cover cosmetic surgery?

Medicare drug price negotiation legal challenge met with skepticism

Stroke rates rising, especially in working

Humana’s losses in Medicare Advantage tank its stock

Some medical students still think black patients feel less pain

Bernie Sanders is gearing up to subpoena pharma CEOs

knowledge

Wikipedia

knowledge

knowledge